Nabriva Therapeutics plc (NBRV) EPS Estimated At $-0.55

March 14, 2018 - By Peter Erickson

 Nabriva Therapeutics plc (NBRV) EPS Estimated At $ 0.55

Analysts expect Nabriva Therapeutics plc (NASDAQ:NBRV) to report $-0.55 EPS on March, 23.They anticipate $0.14 EPS change or 20.29 % from last quarter’s $-0.69 EPS. After having $-0.66 EPS previously, Nabriva Therapeutics plc’s analysts see -16.67 % EPS growth. The stock increased 0.68% or $0.04 during the last trading session, reaching $5.88. About 92,469 shares traded. Nabriva Therapeutics plc (NASDAQ:NBRV) has risen 15.31% since March 14, 2017 and is uptrending. It has underperformed by 1.39% the S&P500.

Nabriva Therapeutics plc (NASDAQ:NBRV) Ratings Coverage

Among 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nabriva Therapeutics had 8 analyst reports since October 12, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 12 by RBC Capital Markets. Leerink Swann initiated Nabriva Therapeutics plc (NASDAQ:NBRV) on Tuesday, October 13 with “Outperform” rating. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) has “Outperform” rating given on Tuesday, October 13 by Wedbush. The stock has “Outperform” rating by Wedbush on Wednesday, February 1. Leerink Swann reinitiated it with “Outperform” rating and $14 target in Thursday, October 27 report. The rating was initiated by RBC Capital Markets on Tuesday, October 13 with “Outperform”. Gabelli initiated it with “Buy” rating and $14 target in Wednesday, January 27 report. The company was initiated on Monday, October 12 by Needham.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company has market cap of $215.75 million. The firm focuses on the pleuromutilin class of antibiotics. It currently has negative earnings. The Company’s lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections.

More important recent Nabriva Therapeutics plc (NASDAQ:NBRV) news were published by: which released: “Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding …” on June 26, 2017, also published article titled: “Nabriva Therapeutics PLC NBRV (US: Nasdaq)”, published: “Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares” on September 18, 2017. More interesting news about Nabriva Therapeutics plc (NASDAQ:NBRV) was released by: and their article: “Nabriva Commences Previously Announced Tender Offer Related to the Proposed …” with publication date: May 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.